S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:DNLI

Denali Therapeutics - DNLI Stock Forecast, Price & News

$31.70
-0.97 (-2.97%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$31.52
$32.81
50-Day Range
$26.28
$32.67
52-Week Range
$20.24
$39.43
Volume
517,900 shs
Average Volume
627,461 shs
Market Capitalization
$4.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.50

Denali Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.5% Upside
$51.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.82mentions of Denali Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.30 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.61) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

59th out of 1,025 stocks

Biological Products, Except Diagnostic Industry

11th out of 168 stocks

DNLI stock logo

About Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Expert Ratings for Denali Therapeutics
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Let's Take a Technical Peek at Denali Therapeutics
Denali Slumps on Drug Candidate Tests
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNLI Company Calendar

Last Earnings
11/04/2021
Today
2/05/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.50
High Stock Price Forecast
$82.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+62.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-290,580,000.00
Net Margins
-273.34%
Pretax Margin
-273.84%

Debt

Sales & Book Value

Annual Sales
$48.66 million
Book Value
$7.88 per share

Miscellaneous

Free Float
118,566,000
Market Cap
$4.31 billion
Optionable
Optionable
Beta
1.37

Key Executives

  • Ryan J. WattsRyan J. Watts
    President, Chief Executive Officer & Director
  • Alexander O. SchuthAlexander O. Schuth
    Secretary, Chief Operating & Financial Officer
  • Carole HoCarole Ho
    Chief Medical Officer & Head-Development
  • Dana Andersen
    CTO & Chief Manufacturing Officer
  • Joe Lewcock
    Chief Scientific Officer













DNLI Stock - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price forecast for 2023?

10 Wall Street research analysts have issued twelve-month target prices for Denali Therapeutics' stock. Their DNLI share price forecasts range from $38.00 to $82.00. On average, they anticipate the company's stock price to reach $51.50 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2023?

Denali Therapeutics' stock was trading at $27.81 on January 1st, 2023. Since then, DNLI shares have increased by 14.0% and is now trading at $31.70.
View the best growth stocks for 2023 here
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.23. The company earned $5.29 million during the quarter, compared to analyst estimates of $30.28 million. Denali Therapeutics had a negative net margin of 273.34% and a negative trailing twelve-month return on equity of 33.85%. Denali Therapeutics's revenue for the quarter was down 43.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) earnings per share.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (11.13%), New York State Common Retirement Fund (0.11%), ProShare Advisors LLC (0.02%), AIA Group Ltd (0.02%), Ironwood Investment Management LLC (0.01%) and Profund Advisors LLC (0.01%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $31.70.

How much money does Denali Therapeutics make?

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.31 billion and generates $48.66 million in revenue each year. The company earns $-290,580,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Denali Therapeutics have?

The company employs 380 workers across the globe.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.

This page (NASDAQ:DNLI) was last updated on 2/6/2023 by MarketBeat.com Staff